health
Gilead and Merck’s latest trial success and flop
Why this matters: health reporting relevant to everyday decisions and well-being.
Good morning. As I’ve been watching the NBA finals, every commercial break has started to sound like&#x A0;this. GSK buys maker of targeted cancer drugs for $10.6B Nuvalent is the latest biotech to be subsumed in the recent wave of pharma acquisitions, my colleague Andrew Joseph reported&#x A0;this morning. The company has two drugs under review by the Food and Drug Administration that target genetic mutations found in lung cancer. Approval decisions on both are expected later this year. Read the rest…
Article preview — originally published by STAT News. Full story at the source.
Read full story on STAT News →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from STAT News alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop